AR097732A1 - Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación - Google Patents

Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación

Info

Publication number
AR097732A1
AR097732A1 ARP140103512A ARP140103512A AR097732A1 AR 097732 A1 AR097732 A1 AR 097732A1 AR P140103512 A ARP140103512 A AR P140103512A AR P140103512 A ARP140103512 A AR P140103512A AR 097732 A1 AR097732 A1 AR 097732A1
Authority
AR
Argentina
Prior art keywords
compositions
factor
heterogenic
populations
coagulation
Prior art date
Application number
ARP140103512A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR097732A1 publication Critical patent/AR097732A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)

Abstract

Composiciones que comprenden variantes recombinantes del factor Xa coagulante humano. Dichas composiciones incluyen una variedad amplia de isoformas y modificaciones post-traducción de FXa y son útiles para tratar sujetos en necesidad de hemostasia.
ARP140103512A 2013-09-24 2014-09-23 Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación AR097732A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24

Publications (1)

Publication Number Publication Date
AR097732A1 true AR097732A1 (es) 2016-04-13

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103512A AR097732A1 (es) 2013-09-24 2014-09-23 Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación

Country Status (19)

Country Link
US (3) US9757434B2 (es)
EP (1) EP3049434A1 (es)
JP (1) JP6429885B2 (es)
KR (1) KR101988705B1 (es)
CN (2) CN112195169A (es)
AR (1) AR097732A1 (es)
AU (1) AU2014326257B2 (es)
BR (1) BR112016005899A8 (es)
CA (1) CA2924981C (es)
HK (1) HK1218760A1 (es)
IL (2) IL244258A0 (es)
MX (1) MX2016003871A (es)
MY (1) MY173548A (es)
PE (1) PE20160877A1 (es)
RU (1) RU2648144C2 (es)
SA (1) SA516370751B1 (es)
SG (1) SG11201601221XA (es)
TW (1) TWI631134B (es)
WO (1) WO2015044836A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015008813A (es) 2013-01-31 2016-03-31 Pfizer Composiciones y metodos para contrarrestar la inhibicion del factor xa.
WO2015044836A1 (en) 2013-09-24 2015-04-02 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EA037815B1 (ru) * 2016-06-17 2021-05-25 Портола Фармасьютикалз, Инк. ПОЛУЧЕНИЕ ПРОИЗВОДНЫХ ФАКТОРА Xa
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
ES2346072T3 (es) * 2004-08-17 2010-10-08 Csl Behring Gmbh Polipeptidos modificados dependientes de la vitamina k.
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
DK2193196T3 (en) * 2007-09-28 2016-11-07 Portola Pharm Inc Clinical profile of Factor Xa inhibitors, and methods of use thereof
RU2567811C2 (ru) 2008-06-24 2015-11-10 Октафарма Аг Способ очистки фактора свертывания крови viii
WO2010056765A2 (en) * 2008-11-14 2010-05-20 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
KR20110114587A (ko) 2008-12-19 2011-10-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도
CA2767858C (en) 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
PT2591006T (pt) * 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
WO2013049804A1 (en) 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
CN104755492A (zh) 2012-07-25 2015-07-01 催化剂生物科学公司 修饰的因子x多肽及其应用
MX2015008813A (es) 2013-01-31 2016-03-31 Pfizer Composiciones y metodos para contrarrestar la inhibicion del factor xa.
WO2015044836A1 (en) 2013-09-24 2015-04-02 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP3063170A4 (en) 2013-11-01 2017-06-28 The Children's Hospital of Philadelphia Compositions and methods for increasing the half-life of factor xa
PT3096779T (pt) 2014-01-24 2020-02-21 Pfizer Composições e métodos para tratamento de hemorragia intracerebral

Also Published As

Publication number Publication date
WO2015044836A1 (en) 2015-04-02
US20170333535A1 (en) 2017-11-23
US9757434B2 (en) 2017-09-12
PE20160877A1 (es) 2016-09-11
JP2016535071A (ja) 2016-11-10
CA2924981A1 (en) 2015-04-02
EP3049434A1 (en) 2016-08-03
IL279396A (en) 2021-01-31
KR101988705B1 (ko) 2019-06-12
US10660946B2 (en) 2020-05-26
RU2016108608A (ru) 2017-10-26
US20210106658A1 (en) 2021-04-15
TWI631134B (zh) 2018-08-01
KR20160044034A (ko) 2016-04-22
SG11201601221XA (en) 2016-04-28
BR112016005899A2 (pt) 2017-09-26
AU2014326257B2 (en) 2017-08-10
CN105579468A (zh) 2016-05-11
HK1218760A1 (zh) 2017-03-10
SA516370751B1 (ar) 2018-04-05
CN112195169A (zh) 2021-01-08
CA2924981C (en) 2020-03-31
US20150182604A1 (en) 2015-07-02
RU2648144C2 (ru) 2018-03-22
AU2014326257A1 (en) 2016-03-10
MY173548A (en) 2020-02-04
TW201524996A (zh) 2015-07-01
IL244258A0 (en) 2016-04-21
JP6429885B2 (ja) 2018-11-28
BR112016005899A8 (pt) 2018-02-06
MX2016003871A (es) 2016-08-04

Similar Documents

Publication Publication Date Title
CO7240393A2 (es) Composiciones que comprenden un aptámero anti-factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista del factor de crecimiento endotelial vascular (vegf)
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
DK3377637T3 (da) Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
TR201903840T4 (tr) İnsan tamamlayıcı C5'e bağlanan polipeptitler.
CO2018006297A2 (es) Composiciones y métodos para disminuir la expresión de tau
BR112017026303A2 (pt) composição de lenço com gel compreendendo fibra de gel superabsorvente
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
AR097732A1 (es) Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
DK3074008T3 (da) Forbindelser, farmaceutisk sammensætning og fremgangsmåder til anvendelse i behandling af inflammation
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
EA201690855A1 (ru) Эндоглиновые пептиды для лечения фиброзных заболеваний
BR112018012749A2 (pt) composições para higiene pessoal
MX2019005693A (es) Factor viii direccionado a los globulos rojos y metodo para su uso.
CY1121749T1 (el) Προφαρμακα ανταγωνιστων nmda
MX2015011418A (es) Tratamiento de enfermedades con nanofibras de poli-n-acetilglucosamina.
BR112018011789A2 (pt) uso inovador
MX358845B (es) Combinacion sinergica de alanina-glutamina, acido hialuronico y un extracto de avena y su uso en una composicion destinada para la curacion de heridas y reparacion de lesiones de la piel.
EA201692161A1 (ru) Прогемостатические белки для лечения кровотечений
PH12014501044B1 (en) Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells
PH12016500509A1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
PH12016501608A1 (en) Peptides and methods of use
GT201000070A (es) Péptido (dn81) optimizado inhibitorio de la entrada del virus del dengue

Legal Events

Date Code Title Description
FB Suspension of granting procedure